SCHEMBL3882949

SCHEMBL3882949

C[C@H](NC(=O)OC(C)(C)C)C(=O)N1C2=C(CCCC2)C[C@H]1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.40
ACE P12821 2/20 0.36
HRH2 P25021 2/20 0.35
HRH1 P35367 2/20 0.35
CTSL P07711 3/20 0.34
CTSK P43235 2/20 0.34
CTSB P07858 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
CMA1 P23946 1/20 0.33
MME P08473 1/20 0.33
PREP P48147 1/20 0.33
BTK Q06187 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067087 0.77 ACE (0.34) ACE
SCHEMBL3885067 0.77 ACE (0.48) ACE
SCHEMBL5377148 0.73 ACE (0.60) ACEMME
SCHEMBL17348387 0.71 ACE (0.53) KMT2AACEHRH1KDM4EMAPT
SCHEMBL6242739 0.71 ACE (0.53) KMT2AACEHRH1KDM4EMAPT
SCHEMBL16000759 0.71 ACE (0.53) KMT2AACEHRH1KDM4EMAPT
SCHEMBL2262901 0.71 ACE (0.53) KMT2AACEHRH1KDM4EMAPT
SCHEMBL13950858 0.71 ACE (0.53) KMT2AACEHRH1KDM4EMAPT
SCHEMBL5564856 0.70 ACE (0.45) ACEMME
SCHEMBL19181306 0.70 ACE (0.43) ACEMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534896-B2 Process for the synthesis of perindopril and its pharmaceutically acceptable salts LES LABORATORIES SERVIER (FR) 2009-05-19 US disclosed
US-7183308-B1 Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof LES LABORATOIRES SERVIER (FR) 2007-02-27 US disclosed
US-20070043103-A1 NOVEL METOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2007-02-22 US disclosed
US-20070010572-A1 NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2007-01-11 US disclosed
EP-1380590-B1 Method for synthesis of perindopril and its pharmaceutically acceptable salts SERVIER LAB (FR) 2006-09-06 EP disclosed
EP-1380591-B1 Method for synthesis of perindopril and its pharmaceutically acceptable salts SERVIER LAB (FR) 2005-11-16 EP disclosed
EP-1371659-B1 Method for synthesis of perindopril and its pharmaceutically acceptable salts [2003/26] SERVIER LAB (FR) 2005-10-12 EP disclosed
EP-1403277-B1 Method for synthesis of (2S,3aS,7aS)-1-((S)-alanyl)-octahydro-1H-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril SERVIER LAB (FR) 2005-10-05 EP disclosed
WO-2005023842-A1 NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2005-03-17 WO disclosed
WO-2005023843-A1 NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2005-03-17 WO disclosed
WO-2005023841-A1 NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2005-03-17 WO disclosed
WO-2004078708-A2 NOVEL METHOD FOR SYNTHESISING DERIVATIVES OF (2S, 3AS, 7AS)-1-[(S)-ALANYL]-OCTAHYDRO,-IH-INDOLE-2-CARBOXYLIC ACID AND THE USE THEREOF FOR PERINDOPRIL SYNTHESIS LES LABORATOIRES SERVIER (FR) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043103-A1 NOVEL METOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF ACE, REN, QDPR KMT2A 2719/4885ACE 1/4885HRH2 2955/4885
US-20070010572-A1 NOVEL METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF ACE, QDPR, REN KMT2A 3110/4885ACE 1/4885HRH2 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.